Kiniksa Pharmaceuticals Interna (KNSA) Q3 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure · Editorial policy
Key numbers
- Adjusted EPS
- $0.56
- Estimate
- $0.31
- Surprise
- +79.2%
- Revenue (period 2026-09-30)
- $286.0M
- Score at report (before → after)
- 6.7 → 6.8/10
Revenue source: xbrl.
How the report landed
Kiniksa Pharmaceuticals Interna (KNSA) beat the $0.31 estimate with adjusted EPS of $0.56 — a large 79.2% upside surprise. TrendMatrix's engine moved from Hold (6.7/10) to Buy (Wait) at 6.8/10 after the report.
Where TrendMatrix's rating stands now
TrendMatrix currently rates KNSA Buy (Wait) at 7.1/10.
3 of the last 4 quarters beat the estimate; this quarter's +79.2% surprise compares with a +24.0% four-quarter average. Next scheduled report: 2027-02-23.
What supports the rating
- V7 quality resilience bonus: +0.2 (Q=7.7 in RISK_OFF)
- Sector modifier (Healthcare): +0.5
What argues against it
- Concentration risk — Product: ARCALYST
- Concentration risk — Supplier: Regeneron
- Analyst target reached - limited upside remaining
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $95.18
- Entry target
- $90.54
- Stop
- $84.20
The stock trades at 72.1× trailing but 46.0× forward earnings — consensus estimates already build in a substantial earnings recovery.
Risk check: trading volume is running 2.1× its average — elevated turnover around the report window.
Model outputs from TrendMatrix’s engine as of 2026-10-29 — shown for context, not personalized investment advice.
KNSA at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Drug Manufacturers - Specialty & Generic
- Market cap
- $7.32B
- P/E (fwd)
- 46.0
- P/E (ttm)
- 72.1
- 52-week range
- $36.56–$95.28
- Off 52-week high
- 0.1%
- RSI (14)
- 69
- Volume vs avg
- 2.15×
- Score today
- 7.1/10